Perceptive Advisors LLC Acquires 124,725 Shares of Artivion, Inc. (NYSE:AORT)

Perceptive Advisors LLC raised its holdings in Artivion, Inc. (NYSE:AORT) by 4.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,793,703 shares of the company’s stock after acquiring an additional 124,725 shares during the period. Artivion comprises about 1.7% of Perceptive Advisors LLC’s investment portfolio, making the stock its 14th largest holding. Perceptive Advisors LLC owned about 0.07% of Artivion worth $71,658,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. nVerses Capital LLC bought a new stake in Artivion in the 2nd quarter valued at $28,000. GAMMA Investing LLC boosted its position in Artivion by 38.6% during the 1st quarter. GAMMA Investing LLC now owns 1,814 shares of the company’s stock worth $38,000 after acquiring an additional 505 shares during the last quarter. RiverPark Advisors LLC acquired a new stake in shares of Artivion in the second quarter valued at approximately $55,000. Register Financial Advisors LLC bought a new stake in shares of Artivion in the first quarter worth $114,000. Finally, Allspring Global Investments Holdings LLC boosted its stake in shares of Artivion by 291.3% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 5,580 shares of the company’s stock worth $118,000 after buying an additional 4,154 shares during the last quarter. 86.37% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently commented on AORT. Stifel Nicolaus increased their price objective on Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a report on Friday, September 13th. Needham & Company LLC reissued a “buy” rating and issued a $30.00 price objective on shares of Artivion in a research report on Friday. Lake Street Capital upped their target price on shares of Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, July 2nd. Finally, Oppenheimer lifted their price target on Artivion from $25.00 to $30.00 and gave the stock an “outperform” rating in a report on Friday, August 9th.

Artivion Trading Up 4.2 %

Shares of NYSE:AORT opened at $26.85 on Monday. The business’s 50 day simple moving average is $25.84 and its 200 day simple moving average is $23.89. Artivion, Inc. has a 1 year low of $12.16 and a 1 year high of $29.24. The company has a debt-to-equity ratio of 1.07, a current ratio of 5.63 and a quick ratio of 4.04. The company has a market capitalization of $1.12 billion, a P/E ratio of -111.88 and a beta of 1.74.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.04. The business had revenue of $98.02 million during the quarter, compared to the consensus estimate of $97.70 million. Artivion had a positive return on equity of 3.81% and a negative net margin of 2.22%. On average, research analysts anticipate that Artivion, Inc. will post 0.2 EPS for the current fiscal year.

Insider Buying and Selling at Artivion

In related news, SVP Jean F. Holloway sold 3,167 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $26.55, for a total value of $84,083.85. Following the completion of the transaction, the senior vice president now owns 161,932 shares of the company’s stock, valued at approximately $4,299,294.60. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Artivion news, VP Matthew A. Getz sold 9,420 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $25.31, for a total transaction of $238,420.20. Following the completion of the transaction, the vice president now owns 34,116 shares in the company, valued at approximately $863,475.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Jean F. Holloway sold 3,167 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $26.55, for a total transaction of $84,083.85. Following the completion of the transaction, the senior vice president now owns 161,932 shares in the company, valued at approximately $4,299,294.60. The disclosure for this sale can be found here. Insiders have sold a total of 24,679 shares of company stock worth $626,518 over the last 90 days. Insiders own 8.10% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.